SPONSORED BY:

About

Showcasing achievement and success in the UK and European healthcare, biotech, pharmaceutical and life sciences sectors

The European Mediscience Awards is now in its 20th year, having been held every year since inception in 2002*. The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. Bringing together the best of European mediscience companies to celebrate achievement and recognise success, it is the must-attend event for anybody working in this sector. 

Each year sees the attendance of over 500 quoted and private UK and European life sciences companies and their corporate advisers, analysts, fund managers, commentators and peers. The event is sold out from one year to the next.

The European Mediscience Awards 2022 will take place on Thursday 16 June at the Hotel InterContinental, London,W1.

*with the exception of 2020 when we were unable to hold a live event due to COVID-19, but instead held a successful digital campaign.  

Contact us

Sponsors

Awards

covering the period 1 April 2021 to 31 March 2022

The shortlist is announced

The shortlist Previous winners

Click on each award to view more information

BEST COMMUNICATION AWARD

Sponsored by:

BREAKTHROUGH OF THE YEAR AWARD

Sponsored by:

BEST TECHNOLOGY AWARD

Sponsored by:

THE EMERGING STAR AWARD

Sponsored by:

MEDISCIENCE MEDIA COMMENTATOR OF THE YEAR AWARD

Sponsored by:

CAPITAL MARKET TRANSACTION OF THE YEAR AWARD

Sponsored by:

MOST SIGNIFICANT CONTRIBUTION TO THE MEDISCIENCE SECTOR AWARD

Sponsored by:

BEST NEWCOMER AWARD

Sponsored by:

CHIEF EXECUTIVE OF THE YEAR AWARD

Sponsored by:

COMPANY OF THE YEAR AWARD

Sponsored by:

Voting panel

Ian-Restall_EMA22Judges_1507_new.jpg

Ian Restall

Flathill Communications Group plc

(Voting panel Chairman)

Mette_Kirstine_Agger_2021.jpg

Mette Kirstine Agger

Renee-A-L_EMA22Judges_1539_NEW.jpg

Renée Aguiar-Lucander

Calliditas Therapeutics AB

Vadim-Alexandre_EMA22Judges_1469_NEW.jpg

Vadim Alexandre

SP Angel LLP

Georgia-Atwood.jpg

Georgia Attwood

LifeSci Partners

Nigel-Barnes_2021.jpg

Nigel Barnes

WG Partners

Julia-Bradshaw_EMA22Judges_1505-NEW.jpg

Julia Bradshaw

FTI Consulting

Victoria-Darbyshire_EMA22Judges_1520-NEW.jpg

Victoria Darbyshire

JP Morgan Asset Management

John-Dawson-crop.jpg

John Dawson

Oxford BioMedica plc

Stefan-Hamill_EMA22Judges_1473-NEW.jpg

Stefan Hamill

Numis Securities Ltd

Nooman-Haque_EMA22Judges_1497-NEW.jpg

Nooman Haque

Silicon Valley Bank

Anne_Hennecke_2021.jpg

Anne Hennecke

MC Services AG

Max-Herrmann_EMA22Judges_1451-NEW.jpg

Max Herrmann

Stifel

Ulrich_Kinzel_2021.jpg

Ulrich Kinzel

goetzpartners

Matthew-Neal_EMA22Judges_1463-NEW.jpg

Matthew Neal

Consilium Strategic Communications

Rose-Nguyen_EMA22Judges_1527-NEW.jpg

Rose Nguyen

Baillie Gifford

Nick-Rodgers_EMA22Judges_1439-NEW.jpg

Nick Rodgers

SEHTA

Sachin_Soni_2021.jpg

Sachin Soni

Third Eye Asset Management

Julie-Simmonds_EMA22Judges_1477-NEW.jpg

Julie Simmonds

Panmure Gordon & Co.

Dr-Ivo-Staijen_EMA22Judges_1370-NEW.jpg

Dr Ivo Staijen

HBM Partners AG

Melanie_Toyne-Sewell_2021.jpg

Melanie Toyne-Sewell

Instinctif Partners

Dylan-Van-Haaften_EMA22Judges_1389-NEW.jpg

Dylan Van Haaften

Bryan Garnier & Co.

Ian-Restall_EMA22Judges_1507_new.jpg

Ian Restall

Flathill Communications Group plc(Voting panel Chairman)

Mette_Kirstine_Agger_2021.jpg

Mette Kirstine Agger

Renee-A-L_EMA22Judges_1539_NEW.jpg

Renée Aguiar-Lucander

Calliditas Therapeutics AB

Vadim-Alexandre_EMA22Judges_1469_NEW.jpg

Vadim Alexandre

SP Angel LLP

Georgia-Atwood.jpg

Georgia Attwood

LifeSci Partners

Nigel-Barnes_2021.jpg

Nigel Barnes

WG Partners

Julia-Bradshaw_EMA22Judges_1505-NEW.jpg

Julia Bradshaw

FTI Consulting

Victoria-Darbyshire_EMA22Judges_1520-NEW.jpg

Victoria Darbyshire

JP Morgan Asset Management

John-Dawson-crop.jpg

John Dawson

Oxford BioMedica plc

Stefan-Hamill_EMA22Judges_1473-NEW.jpg

Stefan Hamill

Numis Securities Ltd

Nooman-Haque_EMA22Judges_1497-NEW.jpg

Nooman Haque

Silicon Valley Bank

Anne_Hennecke_2021.jpg

Anne Hennecke

MC Services AG

Max-Herrmann_EMA22Judges_1451-NEW.jpg

Max Herrmann

Stifel

Ulrich_Kinzel_2021.jpg

Ulrich Kinzel

goetzpartners

Matthew-Neal_EMA22Judges_1463-NEW.jpg

Matthew Neal

Consilium Strategic Communications

Rose-Nguyen_EMA22Judges_1527-NEW.jpg

Rose Nguyen

Baillie Gifford

Nick-Rodgers_EMA22Judges_1439-NEW.jpg

Nick Rodgers

SEHTA

Sachin_Soni_2021.jpg

Sachin Soni

Third Eye Asset Management

Julie-Simmonds_EMA22Judges_1477-NEW.jpg

Julie Simmonds

Panmure Gordon & Co.

Dr-Ivo-Staijen_EMA22Judges_1370-NEW.jpg

Dr Ivo Staijen

HBM Partners AG

Melanie_Toyne-Sewell_2021.jpg

Melanie Toyne-Sewell

Instinctif Partners

Dylan-Van-Haaften_EMA22Judges_1389-NEW.jpg

Dylan Van Haaften

Bryan Garnier & Co.

Ian-Restall_EMA22Judges_1507_new.jpg

Ian Restall

Flathill Communications Group plc(Voting panel Chairman)

Mette_Kirstine_Agger_2021.jpg

Mette Kirstine Agger

Renee-A-L_EMA22Judges_1539_NEW.jpg

Renée Aguiar-Lucander

Calliditas Therapeutics AB

Vadim-Alexandre_EMA22Judges_1469_NEW.jpg

Vadim Alexandre

SP Angel LLP

Georgia-Atwood.jpg

Georgia Attwood

LifeSci Partners

Nigel-Barnes_2021.jpg

Nigel Barnes

WG Partners

Julia-Bradshaw_EMA22Judges_1505-NEW.jpg

Julia Bradshaw

FTI Consulting

Victoria-Darbyshire_EMA22Judges_1520-NEW.jpg

Victoria Darbyshire

JP Morgan Asset Management

John-Dawson-crop.jpg

John Dawson

Oxford BioMedica plc

Stefan-Hamill_EMA22Judges_1473-NEW.jpg

Stefan Hamill

Numis Securities Ltd

Nooman-Haque_EMA22Judges_1497-NEW.jpg

Nooman Haque

Silicon Valley Bank

Anne_Hennecke_2021.jpg

Anne Hennecke

MC Services AG

Max-Herrmann_EMA22Judges_1451-NEW.jpg

Max Herrmann

Stifel

Ulrich_Kinzel_2021.jpg

Ulrich Kinzel

goetzpartners

Matthew-Neal_EMA22Judges_1463-NEW.jpg

Matthew Neal

Consilium Strategic Communications

Rose-Nguyen_EMA22Judges_1527-NEW.jpg

Rose Nguyen

Baillie Gifford

Nick-Rodgers_EMA22Judges_1439-NEW.jpg

Nick Rodgers

SEHTA

Sachin_Soni_2021.jpg

Sachin Soni

Third Eye Asset Management

Julie-Simmonds_EMA22Judges_1477-NEW.jpg

Julie Simmonds

Panmure Gordon & Co.

Dr-Ivo-Staijen_EMA22Judges_1370-NEW.jpg

Dr Ivo Staijen

HBM Partners AG

Melanie_Toyne-Sewell_2021.jpg

Melanie Toyne-Sewell

Instinctif Partners

Dylan-Van-Haaften_EMA22Judges_1389-NEW.jpg

Dylan Van Haaften

Bryan Garnier & Co.

Shortlist review

Read more about this year’s shortlisted companies by selecting an award below.

Further award categories will be released shortly. 

Best Communication Award

sponsored by Consilium Strategic Communications

 
The 2022 shortlist:


 

Alliance Pharma plc

Wiltshire-based Alliance Pharma is a leading international healthcare business. The group’s purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Alliance Pharma was one of the top performers in the benchmarking exercise due to its consistently high and clearly demonstrated best practice. The group’s Annual Report contained a forward-looking strategy section, which was underpinned by ESG values and included some engaging case studies. Alliance Pharma’s website was noted as being easy to navigate with a clean design and a wealth of content. 


 

Calliditas Therapeutics AB 

Stockholm-based Calliditas Therapeutics focuses on the development and commercialisation of a product candidate called Nefecon for the treatment of renal disease, IgA nephropathy. The group was also shortlisted for the Best Communication Award last year. 

Calliditas has an active IR team who participate in a large number of investor conferences and events. The group’s Annual Report clearly presents Calliditas’ vision and demonstrates that ESG principles are integral to the group’s values. Calliditas has significantly increased its social media presence in addition to increasing its analyst coverage and engagement with shareholders both in Europe and the US.


 

Ergomed plc 

Surrey-based Ergomed is dedicated to the provision of specialised services to the global pharmaceutical industry and the development of new drugs. The group was also shortlisted last year for the Best Communication Award. 

Ergomed has invested in its IR presence by increasing retail investor media engagements and analyst engagements. The group’s Annual Report demonstrated best practice in several sections, including its strategy and forward-looking focus. Ergomed’s website was noted as being a useful and informative tool and its social media is well managed. 


 

Evotec AG

Hamburg-based Evotec’s mission is to discover and develop highly effective therapeutics and make them globally available to patients. The group’s network of partners includes all of the Top 20 Pharma and hundreds of biotechnology companies, academic institutions, and other healthcare stakeholders.

Evotec was a strong performer in the bench marking exercise. The group’s Annual Report and website were observed to be very engaging due to the inclusion of creative hand-drawn illustrations. Evotec demonstrates the value it places on its employees and wider stakeholders and its risk management section was noted as being detailed and engaging. 


 

Hikma Pharmaceuticals plc

London-based Hikma Pharmaceuticals aims to put better health within reach, every day. The group is a trusted, reliable partner and dependable source of over 670 high-quality generic, specialty and branded pharmaceutical products used by hospitals, physicians and pharmacists across North America, MENA and Europe. 

Hikma demonstrated best practices throughout its annual report, making it a strong performer in the bench marketing exercise. Its leadership statements included future growth and returns for shareholders, in addition to incorporating KPIs, supported by images and graphs. The group’s strong online sustainability section includes diagrams and explanatory videos to help elevate stakeholder engagement. 


 

Medica Group plc

Hastings-based Medica Group is the teleradiology market leader. The group provides hospital radiology departments with independent support to address serious capacity issues in both urgent and non-urgent reporting pathways. It is the trusted partner to over 50% of NHS organisations. 

Medica is committed its IR communication and has some impressive IR content. The group’s Annual Report has an engaging and unique Human Story Q&A, sharing a clinical specialist’s experience of the impact of COVID on radiographers, setting the group apart from its competitors. Medica’s website includes a charity partnership page in the responsibility section, and it makes good use of images and icons throughout. 

Breakthrough of the Year Award

sponsored by FTI Consulting

 
The 2022 shortlist:


 

Arecor Therapeutics plc

Cambridge-based Arecor Therapeutics is a global biopharmaceutical company. The group is using it proprietary formulation technology platform Arestat™, to develop a portfolio of proprietary products in diabetes and other indications. 

Arecor started the year strongly with successful clinical data from its first clinical trials of lead product, AT247, an ultra-rapid insulin. This was quickly followed up with the expansion of its partner portfolio with companies including Lilly, Hikma and Intas. In June, the group successfully floated on AIM, raising £20m, providing funding to further develop its platform. Arecor then closed the year with its second insulin product, AT278, successfully completing its first clinical trials with results at the highest end of the group’s expectations.


 

argenx 

argenx is a global immunology company, based in Belgium. The group partners with leading academic researchers through its Immunology Innovation Program (IIP), to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. 

In December 2021, argenx announced the US FDA had approved VYVGART™ for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. These patients represent approximately 85% of the total gMG population. This significant regulatory milestone represented several breakthroughs for argenx. It was the group’s first approved product, the first and only FDA-approved neonatal Fc receptor blocker, and the first approved therapy designed to reduce pathogenic IgGs, an underlying driver of gMG.


 

AstraZeneca plc 

Cambridge-based AstraZeneca is leading a revolution in oncology. The group’s ambition is to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

In February this year, the group announced positive high-level results from the pivotal DESTINY-Breast04 Phase III trial, which showed AstraZeneca and Daiichi Sankyo’s Enhertu has the potential to redefine how breast cancer is classified and treated. A HER2-directed therapy has never before shown a benefit in patients with HER2-low metastatic breast cancer, therefore these results represent a historic moment and a significant breakthrough for the group.


 

Calliditas Therapeutics AB 

Swedish group Calliditas Therapeutics is focused on the development and commercialisation of the product candidate Tarpeyo, for IgA nephropathy, an orphan chronic autoimmune kidney disease for which there is no treatment available. 

Calliditas’ breakthrough came in December 2021, with the US FDA approval of Tarpeyo to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression. IgAN can progressively lead to the need for dialysis and/or kidney transplantation, however Tarpeyo offers disease-specific treatment for patients with this complicated disease. This approval marks the successful transition for Calliditas to a commercial-stage biopharmaceutical company.


 

Destiny Pharma plc 

Destiny Pharma is a clinical phase biotechnology company, based in Brighton. The group is dedicated to the development of novel anti-infectives, with a focus on infection prevention, based on its “in-house” XF platform. 

In February this year, Destiny Pharma received positive Scientific Advice from the EMA following its review of the group’s proposed XF-73 Nasal gel Phase III programme design. This pivotal Phase III programme is expected to lead to the registration of the XF-73 nasal gel as a new drug in Europe. In addition, Destiny Pharma are continuing discussions with the FDA for Phase III designs in the US. The group estimates that sales could exceed $ 1bn in the US alone.


 

Molecular Partners AG 

Switzerland-based Molecular Partners is a pioneer and developer of an entirely new class of therapeutics. The group aims to transform the lives of people with cancer and other serious diseases through its DARPin therapeutics. 

In January 2022, Molecular Partners announced positive topline results from its Phase II global clinical study of ensovibep in acute COVID-19 ambulatory patients. The results showed approximately 80% reduction of the combined risk of hospitalization, emergency room visits, or death compared to placebo, regardless of vaccination status. Ensovibep offers a differentiated approach to treating COVID-19 through a single molecule that can target up to three parts of the SARS-CoV-2 virus simultaneously to neutralize the virus through cooperative binding.


Best Technology Award

sponsored by MC Services AG

 
The 2022 shortlist:


 

Aptamer Group plc 

York-based Aptamer Group is a leading provider of Optimer® binders for use in research, diagnostics and therapeutics. The group strives to deliver transformational solutions that meet the needs of researchers and developers across  life sciences through use of its proprietary Optimer® technology.

Optimer binders are next-generation aptamer molecules derived from nucleic acids that function as an antibody alternative. Aptamer’s unique approach to Optimer® selection offers novel aptamers tailored explicitly for each custom project. The advantages of Optimer® binders are rapid development, batch-to-batch consistency, and cost-effective manufacturability, in addition to their ability to bind specifically to a broader target range than other affinity molecules.


 

Arecor Therapeutics plc 

Cambridge-based Arecor Therapeutics is a globally-focused biopharmaceutical group. Arecor applies its innovative proprietary formulation technology platform Arestat™, to develop an internal portfolio of proprietary products in diabetes and other indications.

Arecor’s technology has the potential to unlock the future treatment landscape for diabetes, hospital care and many other therapy areas. Clinical data for Arecor’s two lead proprietary pipeline candidates demonstrate the strength of the group’s platform technology, with both products outperforming the market-leading insulins in clinical trials. The value and need for Arecor’s technology is proven by multiple revenue generating partnerships with major pharma and biotechs such as Hikma, Lilly and Intas Pharmaceuticals.


 

ONWARD Medical NV 

ONWARD Medical was formed in 2014 by researchers at the Swiss Federal Institute of Technology. The group’s ARC Therapy is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement in people with spinal cord injury.

ONWARD Medical is developing two technology platforms which have been awarded three Breakthrough Device Designations by the US FDA. The group’s ARC-IM implantable device for spinal cord injury is the culmination of fundamental research over the last 20 years. Data has revealed the concept of calibrated biomimetic spinal cord stimulation in action in upper limb, mobility and blood pressure indications. ONWARD Medical devices are not yet approved for commercial sale, however the group has a claim as a first to market in these SCI indications.


 

Oxford Nanopore Technologies plc 

Headquartered in Oxford, Oxford Nanopore has developed a new generation of DNA/RNA sequencing technology that provides rich data, and is fast, accessible and easy to use. The group makes devices dubbed, the “smartphone of sequencing”, to analyse Covid-19 variants.

Oxford Nanopore has developed a new generation of sensing technology that uses nanopores - nano-scale holes - embedded in high-tech electronics, to perform precise molecular analyses. The group offers the only sequencing technology to combine scalability from portable to ultra-high throughput formats with real-time data delivery and the ability to elucidate accurate biological data through the analysis fragments of native DNA or RNA. Researchers have used nanopore sequencing to generate data essential to combating the spread of COVID-19.


 

Spectral MD Holdings Ltd 

Spectral MD is a predictive analytics company headquartered in Texas and quoted on AIM. The group has developed a platform that uses proprietary AI to predict how a wound will heal which is revolutionising the management of wound care.

Spectral MD has developed a product called DeepView®, which is a multispectral imaging AI technology with US FDA Breakthrough Device Designation status. The product is able to distinguish between damaged and healthy human tissue invisible to the naked eye, providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers. Spectra’s unique and validated wound diagnosis device is enabling clinicians to work more effectively, in addition to achieving better patient outcomes.


 

Transgene

Transgene, based in France, is a biotech company that designs and develops targeted immunotherapy products against cancer. The group is exploiting the mechanisms of the immune response to allow patients to defend themselves against disease.

In November 2021, Transgene reported positive data for its novel individualised cancer vaccine TG4050. This individualized immunotherapy is based on Transgene’s advanced virus engineering platform, myvac, and NEC’s deep expertise in artificial intelligence. TG4050 is designed to educate the immune system against each patient’s most relevant neoantigen targets, tumour-specific antigens created by mutations in the malignant cells. Additional patients have been enrolled across the USA, UK, and France for further trials. 

The event


Sponsorship

Sponsorship opportunities sometimes become available, including sponsorship of an individual award, sponsorship of the official drinks reception or sponsorship of the menu. Sponsorship opportunities are, by their very nature, limited. Costs and availability on request.


Hosting a table

Reservations are available for tables of ten people. Numbers are strictly limited and reservations are taken on a first come, first served basis.


Advertising

Advertising in the brochure is welcomed and enables your key messages to reach a highly targeted audience. The event brochure is available on the night and contains details of the names of all attendees, in alphabetical and table order. Thus it is widely used as a corporate finance reference guide for up to a year after the event.


Bespoke sponsorship opportunities

We offer a range of bespoke sponsorship packages, tailor made to suit your marketing objectives and budget. Further information on request.


Key details for guests

Date

Thursday 16 June 2022

Venue

Ballroom, Hotel InterContinental
One Hamilton Place
Park Lane
London W1J 7QY

Start time

6.00 p.m.   – Drinks reception 
7.30 p.m.   – Dinner 
9.15 p.m.   – Awards 
9.45 p.m.   – After-dinner entertainment 
12.00 midnight – Carriages 

Dress code

Black Tie

Charity collection

A charity collection will be taken up during the course of the evening. Further details to follow.

Location

 
Accommodation

 
Hotel InterContinental

If you wish to book a bedroom for the European Mediscience Awards, a special rate of £340.00 inc. VAT for a Classic Room including breakfast has been secured. Please use the link below, and from the drop down option please choose the attendee option to book the bedroom. 

https://book.passkey.com/go/
EuroMedScienceAwds2022
 

Latest media

Charity

The European Mediscience Awards is proud to announce its support of the charities bccs and Kidney Research UK.

A charity collection was held at the 2021 Awards and the total amount raised, which was split equally between these, two charities was:

£5,324


bccs provides highly professional and well‑supported Social Workers and Counsellors to help children and young people who are in need.

bccs works in the East End of London and Essex with children, young people and their families and schools to help them overcome emotional difficulties, behavioural problems and their root causes. The prime focus of the work is to provide an early intervention service to enable them to address difficulties that may be impeding their educational, social and emotional development.

bccs.org.uk
@bccs_charity

Worldwide, around one in 10 people has chronic kidney disease, for which there is no cure. Here in the UK, 20 people develop kidney failure each day, and around 70,000 are reliant on dialysis or a transplant to stay alive. Over the past decade some progress has been made in treating kidney disease, but not nearly enough, with successive generations experiencing the same life-limiting health problems and inadequate treatments. 

As the largest kidney research charity in the UK, nothing is going to stop us in our urgent mission to end kidney disease. We’re here to be heard, to make a difference, to change the future. 

https://kidneyresearchuk.org